US Supreme Court to hear oral arguments in Medtronic v Boston Scientific

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

US Supreme Court to hear oral arguments in Medtronic v Boston Scientific

The US Supreme Court will hear oral arguments today in a case which may shed light on who has the burden of proof when a patent licensee is accused of infringing the patent.

In Medtronic v Boston Scientific, the court will consider whether a licensee challenging a declaratory judgment must demonstrate that its product does not infringe, or whether the patent holder must prove there was infringement.

The case concerns a device manufactured by Medtronic which treats heart failure, known as cardiac resynchronisation therapy (CRT). The patent is owned by Mirowski Family Ventures, which licensed it to another company called Guidant. In 1991, Medtronic sublicensed the patent to Eli Lilly, which had taken over from Guidant as the party-in-interest.

In 2007, Mirowski claimed several Medtronic products infringed the patents. Medtronic sued for a declaratory judgment of non-infringement.

In all other patent litigation, including other declaratory judgments, the burden of proving infringement is on the patent owner. But in September last year, the Federal Circuit ruled that Medtronic had the burden of proving it did not infringe, because it had brought the action for a declaratory judgment and because it was the licensee.

The Federal Circuit said that since the only remedy sought by Medtronic was having a court declare the products in question to be non-infringing, Medtronic should bear the burden of proving it is entitled to such relief.

“A contrary result would allow licensees to use MedImmune’s shield as a sword—haling licensors into court and forcing them to assert and prove what had already been resolved by license,” wrote Judge Richard Linn on behalf of the panel.

The decision overturned a ruling by the District Court for the District of Delaware, which upheld the validity of the patents but concluded that Medtronic did not infringe.

Medtronic appealed to the Supreme Court in March this year, and the court agreed to hear the case in May.

more from across site and SHARED ros bottom lb

More from across our site

The firm has brought in former Weil IP leaders Doug Lumish and Jeff Homrig as it looks to deepen its patent, trade secrets and ITC bench
Bird & Bird helps GSK score a major injunction as the battle to become the UPC’s busiest division tightens, and overall filings reach a new monthly high
CEO Annette Bach explains how the Danish IP consultancy plans to build on its 65% profit growth while keeping external investment off the table for now
Belgian attorneys have revived fax systems to protect clients’ filing rights, while uncertainty over exposed patent data has left firms struggling to answer questions about the breach
In his first interview since leaving Weil Gotshal & Manges, Chris Henry explains why he returned to Latham and how he plans to bolster its tech disputes offering
As GTA VI underlines the extraordinary value of gaming franchises, lawyers at Clifford Chance say investors need to know the IP behind their next deal can deliver the growth they are paying for
As ‘big law’ invests in IP litigation, trial firms are emerging as a valuable source of seasoned courtroom talent
Six hires across the IP spectrum reflect Orrick’s efforts to better serve tech clients across the IP lifecycle
David Stone, partner at White & Case, argues that the government’s planned reforms will modernise and futureproof UK design law, but leave two of the thorniest problems unresolved
Max Scott will join the firm’s IP transactions group in California, becoming the latest Weil IP partner to secure their future
Gift this article